Literature DB >> 30092151

Guidance toward the implementation of multicriteria decision analysis framework in developing countries.

András Inotai1,2, Huong Thanh Nguyen3, Budi Hidayat4, Talgat Nurgozhin5, Pham Huy Tuan Kiet6, Jonathan D Campbell7, Bertalan Németh1, Nikos Maniadakis8, Diana Brixner9, Kalman Wijaya10, Zoltán Kaló1,2.   

Abstract

INTRODUCTION: Multiple Criteria Decision Analysis (MCDA) is increasingly used in health care mainly because it moves decision-making from ad hoc to an evidence-based and comprehensive process. Developing countries with more restricted financial and human research capacities, however, should consider their own methods of MCDA development and implementation. Areas covered: An MCDA framework to improve procurement decisions of off-patent pharmaceuticals was developed for developing countries and adapted to Indonesia, Kazakhstan and Vietnam during three policy workshops. Based on the experience of these workshops and one joint workshop with international experts and decision makers from multiple developing countries, general recommendations were formulated on how to implement MCDA specifically in developing countries. We provide 17 practical MCDA implementation recommendations in four major areas, including (1) MCDA objectives; (2) technical considerations of MCDA tool; (3) development and customization of MCDA tool and (4) policy implementation of MCDA in decision-making. Expert commentary: These practical MCDA recommendations for developing countries contribute to feasible, transparent, stepwise, iterative and standardized decision-making in health care.

Entities:  

Keywords:  Decision Making; Developing Countries; Implementation Guidance; Multiple Criteria Decision Analysis; Off-patent Pharmaceuticals

Mesh:

Substances:

Year:  2018        PMID: 30092151     DOI: 10.1080/14737167.2018.1508345

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  7 in total

1.  Potential Criteria for Frameworks to Support the Evaluation of Innovative Medicines in Upper Middle-Income Countries-A Systematic Literature Review on Value Frameworks and Multi-Criteria Decision Analyses.

Authors:  Ivett Jakab; Bertalan Németh; Baher Elezbawy; Melis Almula Karadayı; Hakan Tozan; Sabahattin Aydın; Jie Shen; Zoltán Kaló
Journal:  Front Pharmacol       Date:  2020-08-14       Impact factor: 5.810

2.  Priority setting in the Brazilian emergency medical service: a multi-criteria decision analysis (MCDA).

Authors:  Talita D C Frazão; Ana F A Dos Santos; Deyse G G Camilo; João Florêncio da Costa Júnior; Ricardo P de Souza
Journal:  BMC Med Inform Decis Mak       Date:  2021-05-06       Impact factor: 2.796

3.  Stakeholder driven development of a multi-criteria decision analysis tool for purchasing off-patent pharmaceuticals in Kuwait.

Authors:  Ali Hadi Abdullah; Anke-Peggy Holtorf; Maryam Al-Hussaini; Jacinthe Lemay; Maryam Alowayesh; Zoltán Kaló
Journal:  J Pharm Policy Pract       Date:  2019-04-16

4.  Development and Practical Application of a Multiple-Criteria Decision Analysis Framework on Respiratory Inhalers: Is It Always Useful in the MOH Malaysia Medicines Formulary Listing Context?

Authors:  Yee Vern Yong; Siti Hajar Mahamad Dom; Nurulmaya Ahmad Sa'ad; Rosliza Lajis; Faridah Aryani Md Yusof; Jamalul Azizi Abdul Rahaman
Journal:  MDM Policy Pract       Date:  2021-03-30

5.  A multi-criteria decision analysis (MCDA) tool for purchasing off-patent oncology medicines in Egypt.

Authors:  Baher Elezbawy; Ahmad Nader Fasseeh; Amal Sedrak; Randa Eldessouki; Mary Gamal; Mariam Eldebeiky; Hanaa Amer; Shimaa Akeel; Ahmad Morsy; Amira Amin; Amr Shafik; Sherif Abaza; Zoltán Kaló
Journal:  J Pharm Policy Pract       Date:  2022-03-01

6.  Case studies for implementing MCDA for tender and purchasing decisions in hospitals in Indonesia and Thailand.

Authors:  Anke-Peggy Holtorf; Erna Kristin; Anunchai Assamawakin; Nilawan Upakdee; Rina Indrianti; Napassorn Apinchonbancha
Journal:  J Pharm Policy Pract       Date:  2021-06-14

Review 7.  Development of a core evaluation framework of value-added medicines: report 2 on pharmaceutical policy perspectives.

Authors:  Zoltán Kaló; Zsuzsanna Ida Petykó; Frank-Ulrich Fricke; Nikos Maniadakis; Tomáš Tesař; Kateřina Podrazilová; Jaime Espin; András Inotai
Journal:  Cost Eff Resour Alloc       Date:  2021-07-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.